Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Bevacizumab + TP Induction for High-Risk NPC
NCT06752382Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06752382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752382.